^
Association details:
| Biomarker: | HIF1A expression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma
Excerpt:
The HIF1α transcriptional signature (46 samples) was enriched in tumors expressing high HIF1α levels....However, clusters were not associated with ORR (p=0.7455) or PFS (p=0.6058) in patients receiving pazopanib....the HIF1α gene expression signature was not associated with clinical outcome to pazopanib.
DOI:
10.1158/1078-0432.CCR-13-0491
Trial ID:
